MEDS — DataMeds AI, Inc. - Common Stock
Session close: $1.34. Regular-session share volume: 58,136,856. Change from previous close: +84.14%.
Key developments
DataMeds AI agreed to acquire the TBIA cancer AI blood test platform from the Todos Medical estate for its subsidiary Helomics, a certified cancer diagnostics laboratory. The spectroscopy platform previously held European regulatory marks for breast and colorectal cancer tests. Helomics plans to revalidate data correlations with biopsies and imaging and support a lab-developed test launch ahead of regulatory submissions. Issued patents in the United States and Europe are described as providing exclusivity well into the next decade.